Continuous postoperative pericardial flushing method versus standard care for wound drainage after adult cardiac

Eva Diephuis1, Corianne de Borgie2, Anton Tomšič3

  • 1Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Location AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Ebiomedicine
|April 29, 2020
PubMed

Insights

Continuous postoperative pericardial flushing (CPPF) significantly reduces blood loss and bleeding complications after cardiac surgery. This method improves chest tube patency, enhancing patient recovery and safety.

Area of Science:

  • Cardiovascular Surgery
  • Thoracic Surgery
  • Critical Care Medicine

Background:

  • Post-cardiac surgery bleeding complications are common.
  • Inadequate wound drainage and pericardial blood accumulation contribute to morbidity.
  • Continuous Postoperative Pericardial Flushing (CPPF) was developed to address these issues.

Purpose of the Study:

  • To evaluate the efficacy of CPPF in reducing blood loss and bleeding-related complications after cardiac surgery.
  • To assess the impact of CPPF on chest tube patency and patient outcomes.

Main Methods:

  • A single-center, open-label, randomized controlled trial was conducted.
  • 170 adult patients undergoing non-emergent valvular or congenital heart disease surgery were randomized to CPPF or standard care.
  • Primary outcome: blood loss at 12 hours post-ICU stay. Secondary outcomes: bleeding complications and 6-month clinical outcomes.

Main Results:

  • CPPF reduced blood loss by 41% compared to standard care (median difference -155 ml, p≤0.001).
  • No cases of cardiac tamponade or reoperation for bleeding occurred in the CPPF group versus 1 and 3 in the control group, respectively.
  • Patients receiving CPPF had lower rates of pleural effusion at hospital discharge (22% vs. 36%, p=0.043).

Conclusions:

  • CPPF is a safe and effective method for improving chest tube patency and reducing blood loss post-cardiac surgery.
  • CPPF demonstrates potential in mitigating bleeding-related complications.
  • Larger trials are warranted to confirm effectiveness on clinically relevant outcomes.
Abstract